In contrast, this study uses a pan-lysyl oxidase inhibitor, which has successfully completed pre-clinical development, Phase 1 studies, and is currently in Phase 2 for myelofibrosis and hepatocellular carcinoma. Here, LOX is linked to myelofibrosis.